Welcome to the international HTA database

Showing [21811 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2019	Canadian Agency for Drugs and Technologies in Health (CADTH)	Dual antiplatelet therapy following percutaneous coronary intervention: clinical and economic impact of standard versus extended duration
2019	Canadian Agency for Drugs and Technologies in Health (CADTH)	Community water fluoridation programs: a health technology assessment - review of dental caries and other health outcomes
2019	NIHR Health Technology Assessment programme	A contingency management intervention to reduce cannabis use and time to relapse in early psychosis: the CIRCLE RCT
2020	Technology Assessment at SickKids (TASK)	Microcosting of whole genome sequencing (WGS) of trios in heterogeneous pediatric cardiac population
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: prophylactic use of hydroxychloroquine (HCQ)
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Biomarker-based tests to support the decision for or against adjuvant systemic chemotherapy in primary breast cancer - state of knowledge]
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: treatment with hydroxychloroquine (HCQ)
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Gilteritinib (AML) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: infectivity of patients who have recovered from disease
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Avelumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Cytokine adsorption for treatment of COVID-19 disease
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Neratinib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: decontamination and reprocessing of personal protective equipment (PPE)
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (combination with axitinib, renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Transmission of respiratory infections via showers
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (head and neck squamous cell carcinoma, monotherapy) - Benefit assessment according to §35a Social Code Book V]
2020	NIHR Health Technology Assessment programme	Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Remdesivir for treatment of COVID-19 disease
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (head and neck squamous cell carcinoma, combination therapy) - Benefit assessment according to §35a Social Code Book V]
2020	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	Treatment of depression with transcranial magnetic stimulation using an H-coil (dTMS)
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: sedation-ventilation liberation of COVID+ patients
2020	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Hyperbaric oxygenotherapy for fybromialga, peripheral vascular disease, neurological disease and other indications]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dupilumab (chronic rhinosinusitis with nasal polyposis) - Benefit assessment according to §35a Social Code Book V]
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: surgical masks and filtering face piece respirators (FFR) for health care providers
2020	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Effectiveness and safety of endovascular treatment with venous adhesive in varicose veins of the lower extremities]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Newborn screening for spinal muscular atrophy (SMA)]
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: point-of-care (POC) testing
2020	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Analysis of the efficacy and safety of robotic spinal surgery]
2020	Adelaide Health Technology Assessment (AHTA)	Genetic testing for diagnosis of inheritable cardiac rhythm disorders
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (cystic fibrosis, 6 to < 12 months, with gating mutations) - Benefit assessment according to §35a Social Code Book V]
2020	NIHR Health Technology Assessment programme	Best-practice prevention alone or with conventional or biological caries management for 3- to 7-year-olds: the FiCTION three-arm RCT
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: antibiotic management in ambulatory patients
2020	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Clinical effectiveness of pulse oximetry for neonatal screening of critical congenital heart diseases]
2020	Adelaide Health Technology Assessment (AHTA)	Detection of aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein antibody (MOG) antibodies for diagnosis of neuromyelitis optica (NMO) and myelin oligodendrocyte glycoprotein antibody-related demyelination (MARD)
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Atezolizumab (breast cancer) - Addendum to Commission A19-81]
2020	NIHR Health Technology Assessment programme	Total versus partial knee replacement in patients with medial compartment knee osteoarthritis: the TOPKAT RCT
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: temperature screening for healthcare personnel
2020	Andalusian Health Technology Assessment Area (AETSA)	[C-Reactive Protein point-of-care testing (CRP-POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections]
2020	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Hypoglossal nerve stimulation systems for treatment of obstructive sleep apnea]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Atezolizumab (small cell lung cancer) - Addendum to Commission A19-86]
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: criteria for discharging patients from inpatient care
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Larotrectinib (solid tumours with neurotrophic tyrosine receptor kinase [NTRK] gene fusion) - Addendum to Commission A19-90]
2020	Norwegian Institute of Public Health (NIPH)	Safety, clinical effectiveness, predictive accuracy and cost effectiveness of blood based tests for women with suspected preeclampsia: a health technology assessment
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: high flow nasal cannula (HFNC)/non-invasive positive pressure ventilation (NIPPV) indications
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Elotuzumab (multiple myeloma) - Addendum to Commission A19-80]
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: proning considerations for patients on HFNC or BIPAP
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Niraparib (ovarian cancer) - Addendum to Commission A19-88]
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: criteria for advising home care patients to return to the hospital
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Asfotase alfa (hypophosphatasia) - Addendum to Commission A19-89]
2020	NIHR Health Services and Delivery Research programme	Stroke Sentinel Audit Programme: Investigating and Evaluating Stroke Therapy (SSNAPIEST)
2020	Norwegian Institute of Public Health (NIPH)	Intracoronary lithotripsy for the treatment of coronary artery disease: a health technology assessment
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: surge triage for suspected influenza-like illness
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Guideline synopsis for the DMP "COPD"]
2020	NIHR Health Services and Delivery Research programme	An evaluation of a multifaceted intervention to reduce antimicrobial prescribing in care home residents [REducing Antimicrobials in Care Homes (REACH)]: a non-randomised feasibility study and process evaluation
2020	Norwegian Institute of Public Health (NIPH)	Disease modifying drugs for treatment of primary progressive multiple sclerosis: A health technology assessment
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Trastuzumab emtansine (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2020	NIHR Health Services and Delivery Research programme	UK Study of tendon Achilles Rehabilitation multicentre randomised clinical trial (UK STAR)
2020	Scottish Health Technologies Group (SHTG)	The Scottish asynchronous digital dermatology appointment service (DDAS)
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Avelumab (renal cell carcinoma) - Addendum to Commission A19-95]
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[Optimal use guide: pharmacological treatment of sexually transmitted and blood-borne infections ─ infections caused by chlamydia trachomatis and neisseria gonorrhoeae]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Avelumab (renal cell carcinoma) - Addendum to Commission A19-95]
2020	NIHR Health Technology Assessment programme	Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Neratinib (breast cancer) - Addendum to Commission A19-98]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relationship between volume of services and quality of treatment outcome for kidney transplantations - Rapid report]
2020	Canadian Agency for Drugs and Technologies in Health (CADTH)	Condition-level review on tuberculosis: repository of evidence and resources
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Prostate cancer screening with the PSA test]
2020	NIHR Health Services and Delivery Research programme	IMPlementation of A Relatives Toolkit (IMPART study): examining the critical success factors, barriers and facilitators to implementation of an online supported self-management intervention in the NHS
2020	NIHR Health Technology Assessment programme	Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Update PET/PET-CT evidence for need based planning in the area of oncology
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relationship between volume of services and quality of treatment outcome for complex oesophagael interventions - Rapid report]
2020	NIHR Health Technology Assessment programme	Lead-I ECG for detecting atrial fibrillation in patients with an irregular pulse using single time point testing: a systematic review and economic evaluation
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Belimumab (systemic lupus erythematosus in children and adolescents) - Addendum to Commission A19-94]
2020	NIHR Health Technology Assessment programme	Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke: a systematic review and economic evaluation
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Upadacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V]
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Proton and carbon ion therapy - an update on indications
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dulaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2020	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Endovascular treatment of varicose veins by radiofrequency ablation or cyanoacrylate closure]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Polatuzumab vedotin (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	NIHR Health Technology Assessment programme	Oral splints for patients with temporomandibular disorders or bruxism: a systematic review and economic evaluation
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bedaquiline (pulmonary multidrug-resistant tuberculosis) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	NIHR Health Technology Assessment programme	Interventions to reduce the risk of surgically transmitted Creutzfeldt–Jakob disease: a cost-effective modelling review
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ramucirumab (NSCLC, combination with erlotinib) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Daratumumab (multiple myeloma, stem cell transplant) - Benefit assessment according to §35a Social Code Book V]
2020	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Literature review on efficacy and safety of ultraviolet light and ozone for surface disinfection (Update)]
2020	Malaysian Health Technology Assessment (MaHTAS)	Pre-dialysis education programme (PDEP)
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Siponimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2020	Malaysian Health Technology Assessment (MaHTAS)	Diagnostic approaches to solitary pulmonary nodule (SPN)
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tafamidis (wild-type or hereditary transthyretin amyloid cardiomyopathy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Safety and efficacy of Thai massage as a therapeutic intervention in clinical pathologies]
2020	Malaysian Health Technology Assessment (MaHTAS)	Cinacalcet for the treatment of secondary hyperparathyroidism in end stage renal failure and economic evaluation
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ribociclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ribociclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[CT or MRT diagnostics for suspected chronic coronary heart disease: an evidence mapping]
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Bedaquiline (new therapeutic indication: multi-drug-resistant pulmonary tuberculosis, 12 to < 18 years)]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Urinary proteome analysis for detection of diabetic nephropathy in patients with diabetes mellitus and arterial hypertension. Update of Commission D13-01. - Rapid Report]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tisagenlecleucel (B-cell acute lymphoblastic leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2020	Malaysian Health Technology Assessment (MaHTAS)	Influenza vaccination for the elderly and economic evaluation
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tisagenlecleucel (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]